Psychedelic Business Spotlight – December 10

This week in psychedelic business news: Wesana Health files a new patent, Silo Pharma is granted a patent, and 2 companies explore a merger.
Non-Hallucinogenic DMT? Psilera Bioscience Reports Progress on 'Well-Tolerated' Derivative

Non-Hallucinogenic DMT? Psilera Bioscience Reports Progress on ‘Well-Tolerated’ Derivative

,
Further in vivo studies with PSIL-002 will evaluate its antidepressant, anxiolytic, and anti-addictive properties, specifically targeting alcohol consumption.

Psychedelic Business Spotlight: December 3

This week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.
Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy TrialShutterstock.com

Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy Trial

Chief Medical Officer Dr. Guy Goodwin clarifies "COMP360 psilocybin therapy was generally well-tolerated" by patients with treatment-resistant depression, despite some adverse reactions from subjects in the study.
Psychedelic Business Spotlight: November 26

Psychedelic Business Spotlight: November 26

This week in psychedelic business news: Compass Pathways files another patent; Seelos Therapeutics raises big money; Cybin makes psychedelic therapy more accessible in NYC.
PharmaTher Believes Ketamine Could Treat This Rare Neurological ConditionShutterstock.com

PharmaTher Believes Ketamine Could Treat This Rare Neurological Condition

,
The company is also exploring if ketamine can treat other neurological conditions, including Parkinson’s Disease, ALS, and CRPS.
How the COVID Pandemic Inspired Wakeful Travel's Psychedelic Integration Journals

How the COVID Pandemic Inspired Wakeful Travel’s Psychedelic Integration Journals

A travel journal company pivots from external trips to those unfolding in the mind, and the psychedelic community is embracing the one-of-a-kind integration workbook with open arms.

Psychedelic Business Spotlight: November 19

This week in psychedelic business news: Companies partner on new dosage method; MindMed investigates LSD microdosing; Health Canada allows a psilocybin production campus.

Psychedelic Business Spotlight: November 12

This week in psychedelic business news: two of the biggest players in the industry unveil big data; Numinus Wellness helps MAPS expand MDMA study; and Ketamine One announces IPO intention.

Largest Psilocybin Therapy Trial Ever Conducted Shows Depressive Symptoms Rapidly Reduce

,
“A single dose of psilocybin generated a rapid response that lasted up to 12 weeks,” explains principal investigator Dr. David J. Hellerstein, who was evaluating Compass Pathways' novel drug formulation COMP360.